Platelet Rich Plasma: PRP injection into the midurethra and its instillation into urinary bladder
Study summary
The goal of this clinical trial is to assess the efficacy of platelet-rich plasma (PRP) for the treatment of mixed urinary incontinence determine .The main question it aims to answer whether PRP is it safe and effective in managing mixed urinary incontinence? Researchers will assess efficacy of PRP in both stress and urgency incontinence treatment
Participants will:
* Undergo PRP injection in to mid urethra , and installation into bladder every 1 month for 3 month
* Visit the clinic once every 1 month for checkups and urodynamic study after 3 month, and 4 month after last installation
Eligibility
Sex
FEMALE
Min age
20 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:
* Women with MUI ( mild and moderate degree of stress incontinence)
* Age between 20 to 60 years -
Exclusion Criteria:
* intrinsic sphincteric deficiency (ISD)
* Pregnancy
* Sepsis
* Acute and chronic infections
* Chronic liver disease
* Anti-coagulation therapy
* History of malignancy
* Under anti-platelet agent treatment
Primary outcome measure(s)
Number of females with treatment-related improvement of mixed urinary incontinence after receiving platelet-rich plasma (PRP) injection and instillation. — From enrollment to the end of intervention at 6 month " Treatment -related improvement of urinary incontinence is assessed using:
* International consultation on incontinence questionnaire- short form (ICIQ-SF).
* OAB symptom score.
* Cough stress test.
* Urodynamics.
1. ICIQ-Sf questionnaire before and after treatment: Scoring scale: 0-21, minimum 0, maximum 21. A higher score indicates greater impairment from incontinence.
2. OAB symptom score: has a maximum score of 15 with more weight assigned to urgency and urgency incontinence than on frequency. Higher score indicates greater impairment from incontinence.
3. Urodynamics: for assessment of of detrusor over-activity before and after treatment.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
